<code id='641A87AD4A'></code><style id='641A87AD4A'></style>
    • <acronym id='641A87AD4A'></acronym>
      <center id='641A87AD4A'><center id='641A87AD4A'><tfoot id='641A87AD4A'></tfoot></center><abbr id='641A87AD4A'><dir id='641A87AD4A'><tfoot id='641A87AD4A'></tfoot><noframes id='641A87AD4A'>

    • <optgroup id='641A87AD4A'><strike id='641A87AD4A'><sup id='641A87AD4A'></sup></strike><code id='641A87AD4A'></code></optgroup>
        1. <b id='641A87AD4A'><label id='641A87AD4A'><select id='641A87AD4A'><dt id='641A87AD4A'><span id='641A87AD4A'></span></dt></select></label></b><u id='641A87AD4A'></u>
          <i id='641A87AD4A'><strike id='641A87AD4A'><tt id='641A87AD4A'><pre id='641A87AD4A'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:979
          A sign of Lilly on the top of its biotechnology center — coverage from STAT
          Adobe

          Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

          In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

          advertisement

          In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more
          McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources
          McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

          2:29Sen.JohnBarrassoreachesouttohelpSenateMinorityLeaderMitchMcConnellafterMcConnellfrozeandstoppedt

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Websites selling Wegovy, Zepbound ingredients targeted by FDA

          SarahSilbiger/GettyImagesTheFoodandDrugAdministrationiscrackingdownonwebsitesthatclaimtoselltheunder